Last updated: August 20, 2026
Ocrevus, Roche’s ocrelizumab franchise, is one of the largest products in multiple sclerosis. Revenue increased from approximately CHF 3.7 billion in 2019 to CHF 6.4 billion in 2023, driven by new patient starts, conversion from older therapies, broader use in primary progressive multiple sclerosis, and high persistence. Roche’s subcutaneous formulation, Ocrevus Zunovo, gained FDA approval in September 2024 and extends the franchise beyond intravenous infusion.[1][2]
The principal commercial risks are increasing competition from Novartis’ Kesimpta and TG Therapeutics’ Briumvi, slower growth in the mature U.S. market, payer pressure, and eventual biosimilar entry after the U.S. biologic exclusivity and key patent barriers expire. No Ocrevus biosimilar has FDA approval, and no major publicly disclosed Paragraph IV settlement has materially changed the U.S. entry outlook.
How large is the Ocrevus market and how fast is revenue growing?
Ocrevus has moved from launch-product expansion into a scale-growth phase. Roche’s reported sales trajectory is as follows:
| Fiscal year |
Ocrevus sales |
Approximate year-over-year growth |
Principal commercial driver |
| 2019 |
CHF 3.7 billion |
Approximately 27% |
Rapid U.S. uptake |
| 2020 |
CHF 4.6 billion |
Approximately 24% |
Continued conversion from older MS therapies |
| 2021 |
CHF 4.8 billion |
Approximately 5% |
Pandemic-related treatment disruption |
| 2022 |
CHF 5.7 billion |
Approximately 19% |
Recovery in starts and infusion activity |
| 2023 |
CHF 6.4 billion |
Approximately 12% |
New patients, switching, and international growth |
| 2024 |
Approximately CHF 7.1 billion |
Approximately 10% |
Continued demand and subcutaneous formulation launch |
Sources: Roche annual reports and full-year results.[1][3]
Ocrevus represented roughly 11% of Roche’s 2023 group sales, based on reported group revenue of approximately CHF 58.7 billion and Ocrevus sales of CHF 6.4 billion.[1] That concentration gives the product strategic importance beyond its individual indication. The franchise is one of Roche’s largest growth assets and a material contributor to the company’s pharmaceutical division.
What is driving Ocrevus revenue growth?
Ocrevus growth has four main components:
- New diagnoses of multiple sclerosis and treatment initiation.
- Switching from injectable and lower-efficacy disease-modifying therapies.
- Retention of patients on twice-yearly treatment.
- Expansion of the primary progressive multiple sclerosis segment, where Ocrevus was the first FDA-approved disease-modifying therapy.
The product’s six-month dosing schedule reduces administration frequency compared with many injectable therapies. That supports persistence and reduces some treatment burden, although intravenous infusion requires facility capacity and premedication.
The U.S. remains the principal commercial market. International sales provide geographic diversification but are more exposed to government pricing, reimbursement restrictions, tender systems, and slower adoption of high-cost biologics.
How does Ocrevus compare with Kesimpta, Briumvi, and Tysabri?
Ocrevus remains differentiated by its established safety database, twice-yearly administration, and approval in both relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.
| Product |
Active ingredient |
Company |
Administration |
Key commercial position |
| Ocrevus |
Ocrelizumab |
Roche |
IV infusion twice yearly; subcutaneous Ocrevus Zunovo twice yearly in the U.S. |
Large installed base; only major anti-CD20 option with an approved primary progressive MS indication |
| Kesimpta |
Ofatumumab |
Novartis |
Monthly subcutaneous injection |
Convenience and home administration |
| Briumvi |
Ublituximab-xiiy |
TG Therapeutics |
IV infusion initially, then every 24 weeks |
Shorter infusion time and aggressive commercial launch |
| Tysabri |
Natalizumab |
Biogen |
IV or subcutaneous administration |
High-efficacy therapy with distinct JC-virus and progressive multifocal leukoencephalopathy risk management |
| Gilenya and other oral agents |
Fingolimod and other actives |
Multiple companies |
Oral |
Established alternatives, including generic and lower-cost options |
Ocrevus competes most directly with Kesimpta and Briumvi because all target B-cell depletion through CD20 biology. Kesimpta’s monthly self-injection is attractive to patients who prefer home treatment and avoid infusion centers. Ocrevus has an advantage in dosing frequency and accumulated real-world experience. Briumvi competes on infusion duration and commercial contracting.
The competitive balance is indication-specific. Ocrevus retains a stronger position in primary progressive MS because competitors do not have equivalent approved products across that segment. In relapsing MS, competition is broader and switching is more sensitive to convenience, payer placement, treatment persistence, safety monitoring, and physician familiarity.
What is the FDA regulatory status of Ocrevus?
Ocrevus received FDA approval in March 2017 for:
- Relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Primary progressive multiple sclerosis.[4]
The FDA approved Ocrevus Zunovo in September 2024. The formulation combines ocrelizumab with recombinant human hyaluronidase and is administered subcutaneously approximately every six months. Roche stated that administration takes about 10 minutes, compared with the longer IV infusion process for conventional Ocrevus.[2]
The subcutaneous product is commercially important because it can:
- Reduce infusion-center time.
- Increase site-of-care flexibility.
- Improve capacity in clinics with infusion bottlenecks.
- Support switching within the Roche franchise rather than switching to a competing anti-CD20 therapy.
- Create a new formulation patent layer.
The clinical label continues to include warnings concerning infusion-related reactions, infections, reductions in immunoglobulins, and malignancy monitoring, including breast cancer signals identified in clinical development.[4]
What exclusivity protects Ocrevus in the United States?
Ocrevus received 12 years of U.S. reference-product exclusivity as a licensed biologic. Under the Biologics Price Competition and Innovation Act, a biosimilar application referencing Ocrevus generally cannot be approved before the end of the 12-year exclusivity period, subject to the statutory patent and litigation process.[5]
The principal U.S. regulatory milestones are:
| Event |
Date |
| FDA approval of Ocrevus |
March 28, 2017 |
| Earliest end of 12-year reference-product exclusivity |
March 2029 |
| FDA approval of Ocrevus Zunovo |
September 2024 |
| Commercial significance of Zunovo |
Potential extension of franchise durability through formulation and administration patents |
The March 2029 date is the key regulatory biosimilar threshold for the original IV product. It does not establish a guaranteed commercial launch date. A biosimilar sponsor must still address regulatory review, patent certifications, patent litigation, manufacturing readiness, and market-access economics.
What patents protect Ocrevus and its formulations?
Because Ocrevus is a biologic, its U.S. patent strategy is separate from the small-molecule Orange Book system. Patent protection can cover the antibody, antibody sequences, production methods, dosing regimens, formulations, and subcutaneous delivery technology.
Publicly identified Ocrevus-related protection includes an antibody patent family associated with ocrelizumab and Roche/Genentech. U.S. Patent No. 9,493,581 is commonly identified in commercial patent databases as a core anti-CD20 antibody patent associated with the product, with an expiration date in the late 2020s after applicable patent-term adjustments.[6]
The commercial patent estate has several layers:
Core antibody patents
These cover anti-CD20 antibodies and, depending on claim scope, antibody sequences, binding characteristics, or functional activity. Core composition claims are usually the most important barrier to an early biosimilar launch.
Method-of-use patents
Ocrevus-related claims can cover treating multiple sclerosis with an anti-CD20 antibody, including dosing schedules and patient populations. Method-of-use protection is more difficult to enforce against a biosimilar if the sponsor markets a product with carved-out indications or relies on physician prescribing behavior.
Formulation patents
The IV formulation and the subcutaneous Ocrevus Zunovo formulation may be protected by separate patent families. Subcutaneous delivery with hyaluronidase provides Roche with a new patent opportunity even as earlier antibody claims approach expiration.
Manufacturing and process patents
Biologic manufacturing patents can cover cell lines, purification, concentration, stability, container systems, and process controls. These rights may raise development costs and increase technical risk, but they generally do not prevent a biosimilar sponsor from developing a non-infringing process.
Patent expiration dates should be evaluated patent by patent. The 2029 regulatory exclusivity date and the late-2020s expiry of important core patent protection are the main reference points for the original IV product. Zunovo could create later-dated formulation and delivery barriers, but the commercial effect depends on claim breadth, validity, enforcement, and whether a biosimilar can launch an IV-only product without infringing subcutaneous claims.
What is the Orange Book and Purple Book status of Ocrevus?
Ocrevus is not an Orange Book product because the Orange Book principally lists approved small-molecule drug products and associated patents. Ocrevus is a biologic and is tracked through the FDA Purple Book.[7]
The Purple Book records the biologic reference product and regulatory exclusivity information. It does not replicate the Orange Book’s traditional patent-listing framework. As a result:
- Ocrevus patent analysis requires review of public patent records, Roche disclosures, FDA exclusivity data, and litigation records.
- A biosimilar sponsor does not use a conventional Orange Book Paragraph IV certification.
- The BPCIA patent-exchange process, commonly called the patent dance, governs the principal U.S. biosimilar pathway.
- The absence of an Orange Book listing does not mean the product lacks patent protection.
Which companies are challenging Ocrevus?
The most important commercial challengers are Novartis, TG Therapeutics, and Biogen rather than generic-drug companies.
Kesimpta is the strongest home-administration competitor. Its monthly injection model directly challenges Ocrevus’ infusion-center model and could capture patients who prioritize convenience over twice-yearly dosing.
Briumvi is a direct anti-CD20 competitor with a shorter infusion proposition. TG Therapeutics has targeted neurologists and infusion practices where faster administration can improve clinic throughput.
Tysabri remains relevant for physicians seeking high-efficacy treatment with a different mechanism and monitoring profile. Oral disease-modifying therapies also compete for newly diagnosed patients and for patients who prefer noninfusion treatment.
No FDA-approved biosimilar to ocrelizumab has entered the U.S. market. The absence of a biosimilar does not eliminate future risk. Ocrelizumab is an established antibody target with substantial commercial value, making it a likely candidate for biosimilar development as the 2029 regulatory threshold approaches.
What generic or biosimilar launch risks exist for Ocrevus?
The first post-exclusivity entrants are more likely to be biosimilars than traditional generics. The launch sequence could develop in stages:
| Period |
Likely market condition |
| Through 2028 |
Roche retains strong protection from regulatory exclusivity and active patent rights |
| 2029 |
Earliest major U.S. biosimilar approval window for the original reference product |
| 2029-2031 |
Potential litigation, settlements, limited launches, or one or more biosimilar entries |
| After 2030 |
Greater price pressure if multiple biosimilars obtain interchangeability or preferred payer status |
| Following Zunovo patent disputes |
Potential split between IV biosimilar competition and protected subcutaneous franchise |
The most likely initial biosimilar strategy is an IV formulation that competes with the original Ocrevus presentation. Roche could preserve a premium segment through Zunovo if subcutaneous formulation, delivery, or administration claims remain enforceable.
The financial impact will depend on the number of entrants and payer behavior. A single biosimilar may produce moderate discounts. Multiple entrants can create rapid net-price erosion, especially where payers use formulary exclusion or preferred-product contracting.
What Ocrevus patent litigation and settlements affect market entry?
There is no widely reported, major U.S. Ocrevus Paragraph IV settlement that has established a public launch date for a named biosimilar. The principal near-term legal issue is likely to be the scope and enforceability of Roche’s antibody, dosing, formulation, and delivery patents as biosimilar applicants begin BPCIA negotiations.
Potential disputes may address:
- Validity of antibody composition claims.
- Obviousness of dosing regimens.
- Written-description and enablement requirements.
- Biosimilar manufacturing processes.
- IV versus subcutaneous formulation claims.
- Indication carve-outs for relapsing versus primary progressive MS.
- Infringement by commercial labeling and physician use.
A settlement could permit an earlier entry date while preserving Roche’s formulation franchise. That type of agreement would reduce litigation risk but could accelerate price competition in the IV segment.
How strong is the Ocrevus patent estate?
The estate is commercially strong but time-limited.
Strengths include:
- A large and established reference-product base.
- Multiple regulatory indications.
- Core antibody protection extending beyond launch.
- High switching costs for patients stable on therapy.
- A new subcutaneous formulation.
- Manufacturing complexity that raises biosimilar development costs.
- Strong physician and payer familiarity.
Weaknesses include:
- The 12-year U.S. biologic exclusivity period ends in 2029.
- Core composition protection approaches the late 2020s.
- Method-of-use patents may be vulnerable to label carve-outs.
- Anti-CD20 competition is already established.
- The product’s mechanism is clinically validated, making it attractive to biosimilar developers.
- Zunovo may protect convenience and administration, but it cannot necessarily prevent IV biosimilar entry.
The estate is therefore stronger as a franchise strategy than as a single-patent barrier. Roche’s commercial objective is to shift patients from the original IV presentation to Zunovo before biosimilar competition reaches scale.
How will Ocrevus revenue develop through the late 2020s?
Ocrevus revenue should continue growing before biosimilar entry, but the growth rate is likely to moderate from launch-era levels. The key drivers are increased penetration of high-efficacy therapy, continued conversion from older products, geographic expansion, and uptake of Zunovo.
A simplified commercial trajectory is:
| Phase |
Revenue outlook |
Main variables |
| 2024-2025 |
Continued growth |
Zunovo launch, new starts, franchise retention |
| 2026-2028 |
Mature growth |
Market penetration, payer controls, competition from Kesimpta and Briumvi |
| 2029-2031 |
Elevated erosion risk |
Biosimilar entry, price discounts, contracting |
| After 2031 |
Franchise segmentation |
IV erosion versus Zunovo retention and premium pricing |
Roche’s revenue exposure is material but manageable at group level because Ocrevus is one product within a diversified portfolio. At the pharmaceutical-division level, the impact is more significant. A 20% reduction from a CHF 7 billion annual base would represent approximately CHF 1.4 billion in annual sales pressure before any offset from Zunovo growth or broader MS-market expansion.
Key Takeaways
- Ocrevus sales increased from approximately CHF 3.7 billion in 2019 to CHF 6.4 billion in 2023 and approximately CHF 7.1 billion in 2024.
- Roche’s product has a large installed base, strong persistence, and a differentiated primary progressive MS indication.
- Kesimpta is the main convenience-based competitor; Briumvi is the main direct infusion competitor.
- Ocrevus receives 12 years of U.S. biologic reference-product exclusivity, placing the principal regulatory threshold in March 2029.
- Ocrevus is tracked in the FDA Purple Book, not the Orange Book.
- No FDA-approved ocrelizumab biosimilar has entered the U.S. market.
- Core antibody protection approaches the late 2020s, while formulation and subcutaneous delivery patents may support later Zunovo protection.
- Roche’s most important lifecycle strategy is conversion from IV Ocrevus to Ocrevus Zunovo before biosimilar entry.
- The largest financial risk is rapid IV price erosion after 2029, not an immediate loss of the entire franchise.
- No major publicly disclosed Ocrevus Paragraph IV settlement has established an earlier biosimilar launch date.
FAQs
When does Ocrevus lose U.S. biologic exclusivity?
The 12-year U.S. reference-product exclusivity period is expected to end in March 2029, based on the FDA approval date of March 28, 2017.
Can a biosimilar launch against Ocrevus before March 2029?
FDA approval of a biosimilar referencing Ocrevus is generally blocked by the 12-year reference-product exclusivity period. Patent litigation or settlement terms could still affect the timing of commercial launch after regulatory approval becomes available.
Is Ocrevus listed in the FDA Orange Book?
No. Ocrevus is a biologic and is tracked in the FDA Purple Book. Its patent analysis relies on public patent records, Roche disclosures, and BPCIA litigation rather than a conventional Orange Book listing.
Will Ocrevus Zunovo delay biosimilar competition?
Zunovo may preserve Roche’s subcutaneous segment through formulation and delivery patents, but it is not certain to prevent an IV ocrelizumab biosimilar from entering the market after the original product’s regulatory exclusivity expires.
Which Ocrevus competitor has the greatest commercial threat?
Kesimpta presents the broadest commercial threat because monthly self-administration directly addresses the infusion-center burden. Briumvi is a narrower but important threat in infusion-based treatment, while Ocrevus retains a significant indication advantage in primary progressive MS.
References
-
Roche. (2024). Annual report 2023. F. Hoffmann-La Roche Ltd.
-
Roche. (2024, September 13). FDA approves Ocrevus Zunovo for people with multiple sclerosis. F. Hoffmann-La Roche Ltd.
-
Roche. (2025). Annual report 2024. F. Hoffmann-La Roche Ltd.
-
U.S. Food and Drug Administration. (2017). Ocrevus prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). Biologics Price Competition and Innovation Act of 2009. FDA.
-
U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,493,581: Anti-CD20 antibodies and uses thereof. USPTO.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
